Extended Data Table 3 Stability of RAY1216 and formation of the P1 R-epimer ‘RAY1216-E’ in plasmas of different species

From: Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir

  1. Percentage (%) remaining of RAY1216 and percentage (%) formation of RAY1216-E at different time points in plasmas of different species are reported. Half-lives (T1/2) of RAY1216 in plasmas of different species are reported in minutes (min).
  2. Source data
Back to article page